Recent

% | $
Quotes you view appear here for quick access.

Watson Pharmaceuticals, Inc. Message Board

apgarvey 7 posts  |  Last Activity: Dec 15, 2014 11:12 AM Member since: Dec 17, 1997
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Aren't many of their products petroleum based? How much will profit for Celanese increase due to lower oil prices?

    Sentiment: Buy

  • Reply to

    sec inquiry over!!! no enforcement action!!!

    by rraeus Oct 17, 2014 12:30 PM
    apgarvey apgarvey Oct 20, 2014 1:05 PM Flag

    The SEC inquiry was a non-issue to begin with. The mom and pop accounting firm down the street from the factory in Waterbury, Vermont, were simply not prepared for the growth of the company with regard to the Sarbanes-Oxley and IRS rules. They could not count the money fast enough. Read my explanation from 2012 when I wrote exactly why Einhorn was wrong. Now maybe some of his institutional lemmings will stop going over the cliff with him.

    Sentiment: Buy

  • Reply to

    Bought more at $ 140

    by aliceghk Aug 26, 2014 1:48 PM
    apgarvey apgarvey Aug 27, 2014 10:00 AM Flag

    But, it is important to know the technology here. Most of the competing electronic medical record (EHR) systems except Cerner are really very old technology. ATHN is certainly lagging in parts of their EHR, e.g. portal technology and patient entered data. But, massive consolidation is occurring in the medical delivery system - look in the number of independent private practices in your town. ACA is not likely to be repealed and single payer won't happen, so private insurance is here to stay. Dealing with insurance is the key to future survival of health care providers as payments decrease. Other than Cerner, few systems rival ATHN in dealing with revenue cycle management. With healthcare as 18% of the economy, leading systems in healthcare information management seem hard to short. Some of the fundamentals become meaningless. The problem with shorts is that they are often gamblers like Einhorn who lack an in depth knowledge of the company or industry trends. Again, study the GMCR chart after 2012 when Einhorn famously shorted it.

    Sentiment: Buy

  • Reply to

    Bought more at $ 140

    by aliceghk Aug 26, 2014 1:48 PM
    apgarvey apgarvey Aug 26, 2014 4:59 PM Flag

    A reasonable purchase. Remember this stock is still suffering from the David Einhorn effect. Mr. Einhorns' attempts at stock manipulation are opportunities. Institutional lemmings that follow his shallow musings unload in fright, allowing real investors like you to step in and make money. Some shorts are covering ATHN, but the short squeeze will occur a little later in the year as everyone realizes Mr. Einhorn's predictions are wrong again. Study the GMCR chart and Message Board: compare my comments on the short arguments to see how this chart will evolve. All the same macro issues apply...what exactly is the short argument here-people will stop seeing doctors?

    Sentiment: Buy

  • Reply to

    Do the folks in Atlanta know more than Einhorn?

    by apgarvey May 13, 2014 8:18 AM
    apgarvey apgarvey May 13, 2014 1:53 PM Flag

    LOL. Start with Einhorn's credentials. What does he really know, what does he believe, and what does he guess about? He provides entertainment value, not investment advice. He tricks institutional lemmings that buy his underperforming fund or sell on his pontifications. Portfolio re-balancing by investment managers using computer algorithms to protect their jobs allows true investors to make real money from bluster and buffoonery. Stay long, my friend.

    Sentiment: Buy

  • Reply to

    Do the folks in Atlanta know more than Einhorn?

    by apgarvey May 13, 2014 8:18 AM
    apgarvey apgarvey May 13, 2014 10:07 AM Flag

    Exactly...these people are no smarter than people on this message board. To quote Peter Lynch..."it's hard to fight the tape."

    Sentiment: Buy

  • Is anyone really still short this stock? I still cannot understand the logic. Yes, in 2012 the mom and pop management was not ready for the likes of hedge fund gamblers and stock cheaters (see his UK fine) like Einhorn. Every one of his postulates were proved wrong (see my posts starting when at $58). There is new management now. What is the short argument? Einhorn brought more attention to a good company doing good things. I will join the folks from Atlanta who are obviously long this one.

    Sentiment: Buy